Rituximab biosimilar (Kashiv BioSciences)

利妥昔单抗生物类似药 (Kashiv BioSciences)

Report date: 2025/05/06 15:48:37

Base Information

Drug NameRituximab biosimilar (Kashiv BioSciences)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibodyBiologics > Biosimilar
Mechanisms of ActionAnti-CD20CD20-directed cytolytic effectsComplement dependent cytotoxicity (CDC) effects +[4] 
TargetsB-lymphocyte antigen CD20
Therapy Area/IndicationsAutoimmune Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesAdello Biologics Llc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesKashiv BioSciences LLC
Active IndicationsN/A
Inactive IndicationsAutoimmune Diseases

Other Information

ATC CodeN/A
Related LinksN/A